Tvardi Therapeutics, Inc.: Pruritus trials

The registry lists 15 Pruritus studies with Tvardi Therapeutics, Inc. as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 2 7Phase 3 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03998163Phase 3Results posted
• CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03636269Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusCompletedNCT03617536Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)CompletedNCT03422653Phase 3Results posted
• Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT03281538Phase 3Results posted
• Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusCompletedNCT02858726Phase 2/3Results posted
• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia ParestheticaTerminatedNCT05978063Phase 2/3
• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic DermatitisTerminatedNCT05387707Phase 3
• CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedNCT05356403Phase 3
• A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusTerminatedNCT05342623Phase 3
• Intermediate-Size Patient Population Expanded Access Program for Intravenous DifelikefalinApproved for marketingNCT05031546
• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)CompletedNCT04706975Phase 2
• Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisCompletedNCT04018027Phase 2
• Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe PruritusTerminatedNCT03995212Phase 2
• Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic PruritusCompletedNCT02229929Phase 2